Endogenous angiogenesis inhibitors as therapeutic agents: historical perspective and future direction

Area of Science:

• Biomedical Sciences
• Oncology
• Pharmacology

Background:

• Angiogenesis, the formation of new blood vessels, is a critical process in tumor growth and metastasis.
• It is regulated by a balance of pro-angiogenic and anti-angiogenic factors, presenting therapeutic targets.
• Inhibiting angiogenesis is an emerging strategy in cancer treatment with agents in clinical development.

Purpose of the Study:

• To review patent literature concerning angiogenesis inhibitors from 2000-2005.
• To focus on the discovery and development of endogenous angiogenesis inhibitors.
• To provide a structured overview of patents targeting various stages of the angiogenic process.

Main Methods:

• Systematic review of patent literature.
• Analysis of patents filed between 2000 and 2005.
• Categorization of inhibitors based on their targets within the angiogenic pathway.

Main Results:

• Identification of numerous patents disclosing endogenous angiogenesis inhibitors.
• Characterization of diverse strategies targeting different steps of angiogenesis.
• Summary of key attributes of these inhibitors as potential antitumor agents.

Conclusions:

• The patent literature from 2000-2005 highlights significant advancements in endogenous angiogenesis inhibitors.
• These inhibitors represent a promising class of drugs for cancer therapy.
• Further development of these agents could lead to novel cancer treatments.